These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1845044)

  • 1. Progress with HIV vaccines.
    Biberfeld G; Emini EA
    AIDS; 1991; 5 Suppl 2():S129-33. PubMed ID: 1845044
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
    Earl PL; Sugiura W; Montefiori DC; Broder CC; Lee SA; Wild C; Lifson J; Moss B
    J Virol; 2001 Jan; 75(2):645-53. PubMed ID: 11134278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic and phenotypic variation of HIV-1: impact on AIDS pathogenesis and vaccination.
    Wolfs TF; Nara PL; Goudsmit J
    Chem Immunol; 1993; 56():1-33. PubMed ID: 8383980
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing animal models of AIDS.
    Stott J; Almond N
    Nat Med; 1995 Apr; 1(4):295-7. PubMed ID: 7585052
    [No Abstract]   [Full Text] [Related]  

  • 5. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
    Letvin NL; Robinson S; Rohne D; Axthelm MK; Fanton JW; Bilska M; Palker TJ; Liao HX; Haynes BF; Montefiori DC
    J Virol; 2001 May; 75(9):4165-75. PubMed ID: 11287566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and strategies for AIDS vaccine development.
    Oxford JS; Frezza P; Race E
    Vaccine; 1993; 11(6):612-4. PubMed ID: 8100664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2.
    Biberfeld G; Thorstensson R; Putkonen P
    AIDS Res Hum Retroviruses; 1996 Mar; 12(5):443-6. PubMed ID: 8882330
    [No Abstract]   [Full Text] [Related]  

  • 9. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
    [No Abstract]   [Full Text] [Related]  

  • 10. Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin.
    Rasmussen RA; Montefiori DC; Robinson HL; McClure HM; Ruprecht RM
    J Infect Dis; 2001 Dec; 184(12):1603-7. PubMed ID: 11740737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The quest for vaccines against AIDS: progress and challenges. An overview.
    Schild GC; Stott EJ
    Vaccine; 1991 Nov; 9(11):779-81. PubMed ID: 1759497
    [No Abstract]   [Full Text] [Related]  

  • 12. [Towards a vaccine against HIV: antibodies raised by a gp41 peptide neutralize the virus and inhibit pathogenesis].
    Vieillard V; Debré P
    Biol Aujourdhui; 2015; 209(2):161-6. PubMed ID: 26514385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.
    Mooij P; van der Kolk M; Bogers WM; ten Haaft PJ; Van Der Meide P; Almond N; Stott J; Deschamps M; Labbe D; Momin P; Voss G; Von Hoegen P; Bruck C; Heeney JL
    AIDS; 1998 Mar; 12(5):F15-22. PubMed ID: 9543435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy.
    Haynes BF; Yasutomi Y; Torres JV; Gardner MB; Langlios AJ; Bolognesi DP; Matthews TJ; Scearce RM; Jones DM; Moody MA
    Trans Assoc Am Physicians; 1993; 106():33-41. PubMed ID: 8036743
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of HIV-2 and SIVSM infection in cynomolgus monkeys by active or passive immunization.
    Biberfield G; Putkonen P; Thorstensson R; Norrby E
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1511-3. PubMed ID: 1466992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of linear antigenic sites in the envelope proteins of human immunodeficiency virus (HIV) type 2 and type 1.
    Norrby E; Putkonen P; Böttiger B; Utter G; Biberfeld G
    AIDS Res Hum Retroviruses; 1991 Mar; 7(3):279-85. PubMed ID: 1712215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 neutralization directed to epitopes other than linear V3 determinants.
    Steimer KS; Klasse PJ; McKeating JA
    AIDS; 1991; 5 Suppl 2():S135-43. PubMed ID: 1726953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.